Skip to main content
OpenTrials
Completed

NCT Number: NCT04500808

A Study of Macitentan, in Healthy Japanese Male Participants

The main purpose of this study is to evaluate the safety and tolerability after multiple-dose administrations of macitentan with titration regimen starting from Dose 1 once daily (qd) up to Dose 2 qd in Japanese healthy adult male participants (Part 1) and to evaluate the effect of food on pharmacokinetics of macitentan and its active metabolite (ACT-132577) in Japanese healthy adult male participants with macitentan Dose 3 tablet (Part 2).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

20 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Sumida Hospital

Tokyo, 130-0004, Japan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
  • Blood pressure (after the participant is supine for 5 minutes) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic
  • A participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person. Male participants should also be advised of the benefit for a female partner to use a highly effective method of contraception as condom may break or leak. Recommended highly effective methods of contraception in this study for female partners of male participants to use in addition to the male participant wearing a condom during include: oral hormonal contraception, intrauterine device, intrauterine hormone-releasing system and bilateral tubal occlusion
  • A participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 90 Days after receiving the last dose of study intervention
  • Nonsmoker or smoker habitually smokes no more than 10 cigarettes or equivalent of e-cigarettes, or 2 cigars, or 2 pipes of tobacco per day for at least 6 months before first study drug administration

Exclusion criteria

  • History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency (creatinine clearance below 80 (milliliter per minute) mL/min calculated using Cockcroft-Gault equation), thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or at admission to the study site as deemed appropriate by the investigator
  • History of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin or malignancy, which is considered cured with minimal risk of recurrence)
  • Known allergies, hypersensitivity, or intolerance to macitentan or its excipients
  • Known allergy to heparin or history of heparin-induced thrombocytopenia

Treatment and study plan

Macitentan Dose 1

Drug

Participants will receive Dose 1 of macitentan tablet in Part 1.

Other names: JNJ-67896062

Macitentan Dose 2

Drug

Participants will receive Dose 2 of macitentan tablet in Part 1.

Other names: JNJ-67896062

Macitentan Dose 3

Drug

Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.

Other names: JNJ-67896062

Placebo

Drug

Participants will receive matching placebo from Day 1 up to Day 13.

Primary outcomes

  1. Part 1: Number of Participants with Adverse Events (AEs)

    Time frame: Up to Day 29

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

  2. Part 1: Number of Participants with Adverse Event of Special Interests (AESIs)

    Time frame: Up to Day 29

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. The following are the AEs of special interest in this study: Hypotension: symptomatic hypotension or potentially clinically meaningful decrease in blood pressure, Edema/fluid retention: clinically relevant signs and symptoms of edema and/or fluid retention, Hemoglobin decrease/anemia: events of hemoglobin decrease from baseline of greater than (>) 20 gram per liter (g/L), Liver events: liver aminotransferase abnormalities.

  3. Part 1: Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Up to Day 29

    A SAE is any AE that results in: death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and is a suspected transmission of any infectious agent via a medicinal product, is medically important.

  4. Part 1: Number of Participants with Clinical Laboratory Abnormalities

    Time frame: Up to Day 29

    Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, blood coagulation) will be reported

  5. Part 1: Number of Participants with Abnormalities in ECG Variables

    Time frame: Up to Day 29

    Number of Participants with abnormalities in ECG variables such as: PR, QRS, QT, RR, and QT corrected Fridericia's formulae (QTcF) will be reported.

  6. Part 1: Change from Baseline in Weight

    Time frame: Baseline, up to Day 29

    Change from baseline in body weight in kilograms as a part of physical examination will be reported.

  7. Part 1: Change from Baseline in Height

    Time frame: Baseline, up to Day 29

    Change from baseline in height in centimeters as a part of physical examination will be reported.

  8. Part 2: Plasma Concentration of Macitentan and its Active Metabolite (ACT-132577)

    Time frame: Predose, 3, 5, 7, 8, 9, 10, 12, 16, 24, 48, 72, 120, 168, and 240 hours post dose

    Plasma concentration of macitentan and its active metabolite (ACT-132577) will be reported.

Secondary outcomes

  1. Part 1: Plasma Concentration of Macitentan and its Active Metabolite (ACT-132577)

    Time frame: Day 5 and Day 13 (predose,1, 3, 5, 7, 8, 9, 10, 12, and 16 hours postdose)

    Plasma concentration of macitentan and its active metabolite (ACT-132577) will be reported.

  2. Part 1: Plasma Endothelin-1 (ET-1) Concentrations

    Time frame: Up to Day 29

    Plasma ET-1 concentrations for macitentan and ACT-132577 will be reported.

  3. Part 2: Number of Participants with Adverse Events (AEs)

    Time frame: Up to Day 12

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

  4. Part 2: Number of Participants with Adverse Event of Special Interests (AESIs)

    Time frame: Up to Day 12

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. The following are the AEs of special interest in this study: Hypotension: symptomatic hypotension or potentially clinically meaningful decrease in blood pressure, Edema/fluid retention: clinically relevant signs and symptoms of edema and/or fluid retention, Hemoglobin decrease/anemia: events of hemoglobin decrease from baseline of greater than (>) 20 gram per liter (g/L), Liver events: liver aminotransferase abnormalities.

  5. Part 2: Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Up to Day 12

    A SAE is any AE that results in: death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and is a suspected transmission of any infectious agent via a medicinal product, is medically important.

  6. Part 2: Number of Participants with Clinical Laboratory Abnormalities

    Time frame: Up to Day 12

    Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, blood coagulation, and urine samples) will be reported

  7. Part 2: Number of Participants with Abnormalities in ECG Variables

    Time frame: Up to Day 12

    Number of Participants with abnormalities in ECG variables such as: PR, QRS, QT, RR, and QT corrected Fridericia's formulae (QTcF) will be reported.

  8. Part 2: Change from Baseline in Weight

    Time frame: Baseline, Up to Day 12

    Change from baseline in body weight in kilograms as a part of physical examination will be reported.

  9. Part 2: Change from Baseline in Height

    Time frame: Baseline, Up to Day 12

    Change from baseline in height in centimeters as a part of physical examination will be reported.

Sponsors and collaborators

Lead sponsor

Janssen Pharmaceutical K.K.

Industry

Registry information

Official study title

A Double-blind, Randomized, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macitentan and an Open-label, Randomized, Crossover, Single-dose Study to Evaluate the Effect of Food on Macitentan Pharmacokinetics, in Healthy Japanese Adult Male Participants

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Aug 5, 2020
Registry last updated
Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.